Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Nash D.
    • Other Affiliation: City University of New York
  • Srivastava A.
    • Other Affiliation: City University of New York
  • Shen Y.
    • Other Affiliation: City University of New York
  • Penrose K.
    • Other Affiliation: City University of New York
  • Kulkarni S.G.
    • Other Affiliation: City University of New York
  • Zimba R.
    • Other Affiliation: City University of New York
  • You W.
    • Other Affiliation: City University of New York
  • Berry A.
    • Other Affiliation: City University of New York
  • Mirzayi C.
    • Other Affiliation: City University of New York
  • Maroko A.
    • Other Affiliation: City University of New York
  • Parcesepe A.M.
    • Affiliation: Gillings School of Global Public Health, Department of Maternal and Child Health
  • Grov C.
    • Other Affiliation: City University of New York
  • Robertson M.K.M.
    • Other Affiliation: City University of New York
Abstract
  • This study used repeat serologic testing to estimate infection rates and risk factors in two overlapping cohorts of SARS-CoV-2 N protein seronegative U.S. adults. One mostly unvaccinated sub-cohort was tracked from April 2020 to March 2021 (pre-vaccine/wild-type era, n = 3421), and the other, mostly vaccinated cohort, from March 2021 to June 2022 (vaccine/variant era, n = 2735). Vaccine uptake was 0.53% and 91.3% in the pre-vaccine and vaccine/variant cohorts, respectively. Corresponding seroconversion rates were 9.6 and 25.7 per 100 person-years. In both cohorts, sociodemographic and epidemiologic risk factors for infection were similar, though new risk factors emerged in the vaccine/variant era, such as having a child in the household. Despite higher incidence rates in the vaccine/variant cohort, vaccine boosters, masking, and social distancing were associated with substantially reduced infection risk, even through major variant surges.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Scientific Reports
Journal volume
  • 14
Journal issue
  • 1
Language
  • English
Version
  • Publisher
Funder
  • National Institute of Allergy and Infectious Diseases, NIAID, (3UH3AI133675-04S1)
  • City University of New York, CUNY
  • National Institute of Mental Health, NIMH, (1RF1MH132360)
ISSN
  • 2045-2322
Publisher
  • Nature Research

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 41598_2023_Article_51029.pdf 2024-02-01 Public Download